We are live on ! Find out more

Diagnostics & Research
Stocks Ranked by
Market Capitalization

Name Market cap Price Price
change %
NEO icon
26
NeoGenomics
NEO
$2.23B
$2.23B $17.32 1.65%
PSNL icon
27
Personalis
PSNL
$1.73B
$1.73B $16.21 0.73%
FRNM
28
Freenome Inc
FRNM
$1.54B
$1.54B $14.37 2.84%
OPK icon
29
Opko Health
OPK
$1.17B
$1.17B $1.57 5.37%
CSTL icon
30
Castle Biosciences
CSTL
$988M
$988M $32.33 0.03%
FLGT icon
31
Fulgent Genetics
FLGT
$563M
$563M $20.45 1.64%
MYGN icon
32
Myriad Genetics
MYGN
$327M
$327M $3.42 1.79%
BDSX icon
33
Biodesix
BDSX
$285M
$285M $26.96 3.53%
XGN icon
34
Exagen
XGN
$170M
$170M $7.03 0.86%
IMDX
35
Insight Molecular Diagnostics
IMDX
$137M
$137M $4.20 5.53%
BNR
36
Burning Rock Biotech
BNR
$130M
$130M $12.28 5.68%
QUCY
37
Quantum Cyber N.V.
QUCY
$113M
$113M $1.34 2.19%
MDXH icon
38
MDxHealth
MDXH
$67.2M
$67.2M $0.7046 4.23%
PRPO icon
39
Precipio
PRPO
$48.9M
$48.9M $27.32 1.52%
ADVB
40
Advanced Biomed Inc
ADVB
$13.5M
$13.5M $8.19 7.46%
AMS icon
41
American Shared Hospital Services
AMS
$9.81M
$9.81M $1.47 0%
NDRA icon
42
ENDRA Life Sciences
NDRA
$8.43M
$8.43M $5.62 2.94%
XWEL icon
43
XWELL
XWEL
$8.29M
$8.29M $0.9647 2.34%
VNRX icon
44
VolitionRx Ltd
VNRX
$5.86M
$5.86M $0.3102 8.76%
BIAF icon
45
bioAffinity Technologies
BIAF
$4.78M
$4.78M $7.95 15.3%
ISPC icon
46
iSpecimen
ISPC
$3.7M
$3.7M $1.47 2%
1
2

Diagnostics & Research Stocks at a Glance

Diagnostics and research companies run laboratory testing, imaging, and analytical services, and supply the instruments behind them. Testing volumes are recurring and largely non-discretionary, while research-tools demand follows pharma and academic R&D budgets.

There are 46 Diagnostics & Research industry stocks tracked by Wall St. Rank, worth a combined $814B.

The largest by market cap are Thermo Fisher Scientific (TMO) at $225B, Danaher (DHR) at $141B and Natera (NTRA) at $47.4B.

Among institutional investors, Guardant Health (GH) drew the most net new fund positions in Q2 2026: 158 funds opened new positions, taking total fund holders up 112 (23%) quarter-over-quarter.

Market caps and prices updated daily; fund activity based on aggregated SEC 13F filings for Q2 2026.